OptimizeRx CCO Theresa Greco departing June 15; receives $589K severance, advisory role

Filed June 5, 2026 · Period ending June 1, 2026 · ~1 min read

Key Changes

• medium

  Chief Commercial Officer Theresa Greco separating effective June 15, 2026, following May 11 separation agreement. She will transition to 12-month advisory role through June 2027 with continued equity vesting.

  Item 5.02 verify on EDGAR →
• medium

  Company paying $589K cash severance ($380K salary continuation plus $209K bonus target) plus 12 months health benefits. Greco remains eligible for change-in-control bonus if M&A occurs during advisory period.

  Item 5.02 verify on EDGAR →
• low

  Greco bound by 12-month non-compete and non-solicitation covenants preventing her from joining competitors or recruiting employees, customers, or service providers.

  Item 5.02 verify on EDGAR →